Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04369430 · ClinicalTrials.gov registry record · Phase 2
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
A Phase 2 study, sponsored by Alkahest.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT04369430 is a Phase 2 study that has completed, run by Alkahest. The registered enrollment target is 110 participants.
The verdict
NCT04369430, a Phase 2 study, has completed, sponsored by Alkahest.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.
Interventions
- DRUG Placebo
- DRUG AKST4290
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2021-03-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04369430
The ClinicalTrials.gov registry entry for NCT04369430 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkahest, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04369430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04369430 about?
NCT04369430 is a clinical study titled "Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment". This study will evaluate the efficacy and safety of AKST4290 in subjects with Parkinson's Disease who are currently on stable dopaminergic treatment.
What is the current status of trial NCT04369430?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2020-01-16. Estimated completion is 2021-03-10.
What interventions are being tested in trial NCT04369430?
The interventions under investigation include: Placebo (DRUG), AKST4290 (DRUG).
Who is sponsoring clinical trial NCT04369430?
This trial is sponsored by Alkahest, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.